130 related articles for article (PubMed ID: 10828037)
1. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity.
van Der Kolk DM; Vellenga E; van Der Veen AY; Noordhoek L; Timmer-Bosscha H; Ossenkoppele GJ; Raymakers RA; Müller M; van Den Berg E; de Vries EG
Blood; 2000 Jun; 95(11):3514-9. PubMed ID: 10828037
[TBL] [Abstract][Full Text] [Related]
2. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells.
van der Kolk DM; de Vries EG; Koning JA; van den Berg E; Müller M; Vellenga E
Clin Cancer Res; 1998 Jul; 4(7):1727-36. PubMed ID: 9676848
[TBL] [Abstract][Full Text] [Related]
3. Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Döhner K; Schlenk RF; van der Reijden BA; Döhner H
Leukemia; 2000 Jun; 14(6):1154. PubMed ID: 10865983
[No Abstract] [Full Text] [Related]
4. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias.
Kuss BJ; Deeley RG; Cole SP; Willman CL; Kopecky KJ; Wolman SR; Eyre HJ; Callen DF
Leuk Lymphoma; 1996 Feb; 20(5-6):357-64. PubMed ID: 8833390
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
6. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.
van der Kolk DM; de Vries EG; Noordhoek L; van den Berg E; van der Pol MA; Müller M; Vellenga E
Leukemia; 2001 Oct; 15(10):1544-53. PubMed ID: 11587212
[TBL] [Abstract][Full Text] [Related]
7. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
Leith CP; Kopecky KJ; Chen IM; Eijdems L; Slovak ML; McConnell TS; Head DR; Weick J; Grever MR; Appelbaum FR; Willman CL
Blood; 1999 Aug; 94(3):1086-99. PubMed ID: 10419902
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
9. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
[TBL] [Abstract][Full Text] [Related]
10. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
11. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
12. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.
Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
Blood; 1998 Jun; 91(12):4480-8. PubMed ID: 9616142
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood.
Laupèze B; Amiot L; Payen L; Drénou B; Grosset JM; Lehne G; Fauchet R; Fardel O
Life Sci; 2001 Feb; 68(11):1323-31. PubMed ID: 11233999
[TBL] [Abstract][Full Text] [Related]
14. Role of MRP1 in multidrug resistance in acute myeloid leukemia.
Legrand O; Zittoun R; Marie JP
Leukemia; 1999 Apr; 13(4):578-84. PubMed ID: 10214864
[TBL] [Abstract][Full Text] [Related]
15. Expression of the human major vault protein LRP in acute myeloid leukemia.
Hart SM; Ganeshaguru K; Scheper RJ; Prentice HG; Hoffbrand AV; Mehta AB
Exp Hematol; 1997 Nov; 25(12):1227-32. PubMed ID: 9357965
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of multidrug resistance related mRNA expression and c-jun-N-terminal kinase activity in patients with acute myeloid leukemia].
Do JH; Oh SH; Song EJ; Chung JS; Kang CD; Lee EY
Korean J Lab Med; 2007 Aug; 27(4):229-36. PubMed ID: 18094581
[TBL] [Abstract][Full Text] [Related]
17. Detection of MRP functional activity: calcein AM but not BCECF AM as a Multidrug Resistance-related Protein (MRP1) substrate.
Olson DP; Taylor BJ; Ivy SP
Cytometry; 2001 Apr; 46(2):105-13. PubMed ID: 11309820
[TBL] [Abstract][Full Text] [Related]
18. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.
Zhou DC; Zittoun R; Marie JP
Leukemia; 1995 Oct; 9(10):1661-6. PubMed ID: 7564506
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis.
Marlton P; Claxton DF; Liu P; Estey EH; Beran M; LeBeau M; Testa JR; Collins FS; Rowley JD; Siciliano MJ
Blood; 1995 Feb; 85(3):772-9. PubMed ID: 7833479
[TBL] [Abstract][Full Text] [Related]
20. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications.
Kuss BJ; Deeley RG; Cole SP; Willman CL; Kopecky KJ; Wolman SR; Eyre HJ; Lane SA; Nancarrow JK; Whitmore SA
Lancet; 1994 Jun; 343(8912):1531-4. PubMed ID: 7911871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
